Short answer
Boston Scientific (BSX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). 2027 annual bonus plan approved for executives and eligible employees, with payouts tied to global sales and adjusted EPS.
Boston Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- 2027 annual bonus plan approved for executives and eligible employees, with payouts tied to global sales and adjusted EPS
- Companywide bonus distribution 0%-150%, plus individual performance modifiers up to 150%
- Maximum individual annual bonus payout: 225% of target, with quality performance potentially reducing payouts
- 2027-2029 rTSR performance shares benchmarked against the S&P 500 Healthcare Index, with awards ranging 0%-200% of target
- 2027-2029 organic sales performance shares tied to financial-plan performance, also ranging 0%-200% of target
Item 8.01 · Other Events
- David S. Wichmann becomes Lead Independent Director effective January 1, 2027
- Edward J. Ludwig relinquishes the lead role after serving since 2016, remaining on the Board
- Wichmann’s appointment preserves board continuity, with prior service since 2021
- Wichmann currently chairs the Audit Committee and serves on the Risk, Science and Technology Committee
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Boston Scientific 8-K filings
Get the next BSX 8-K as it lands
Follow BSX for push alerts, or ask the research agent what this filing means.